Publications by authors named "V Drvota"
Objectives: In the Euroinject One phase II randomized double-blind trial, therapeutic angiogenesis of percutaneous intramyocardial plasmid gene transfer of vascular endothelial growth factor (phVEGF-A(165)) on myocardial perfusion, left ventricular function, and clinical symptoms was assessed.
Background: Evidence for safety and treatment efficacy have been presented in phase I therapeutic angiogenesis trials.
Methods: Eighty "no-option" patients with severe stable ischemic heart disease, Canadian Cardiovascular Society functional class 3 to 4, were assigned randomly to receive, via the NOGA-MyoStar system (Cordis Corp.
ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium.
Biochem Biophys Res Commun
September 2004
Angiogenic gene therapy in angina pectoris has been disappointing so far. Reasons might be that the administered genes already are overexpressed in ischemic myocardium, or that atrial and brain natriuretic peptides (ANP and BNP) are overexpressed, as they have anti-angiogenic effects. Five stable angina pectoris patients without heart failure were studied.
View Article and Find Full Text PDFObjective: It is thought that adult human mesenchymal stem cells do not induce immunoreactivity even to xenografts. We wanted to study whether adult human mesenchymal stem cells survive and engraft in experimentally induced ischemic rat myocardium.
Methods: Bone marrow-derived adult human mesenchymal stem cells (2.
Background And Aim: Local modulation of myocardial function by gene transfer or cell depositions constitutes a potential method of cardiac treatment. This study tested the morphology of myocardial plasmid gene transfer by catheter-based transendocardial injection (NOGA).
Methods: Left ventricular morphology and electrical and mechanical characteristics were mapped in three dimensions.